文献速递银屑病与炎症性皮肤病

银屑病中肿瘤坏死因子α抑制剂生物类似药的 uptake:BADBIR 药物利用研究

Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
PubMed 文献 · Br J Dermatol · 2023-01-01

本研究利用英国皮肤科医师协会生物制剂与免疫调节剂注册登记(BADBIR)数据,描述英国和爱尔兰银屑病患者中 TNFi 生物类似药的使用趋势。原研药使用者队列共 4202 例,英夫利西单抗、依那西普和阿达木单抗 3 年累积转换率分别为 14.8%、23.6% 和 66.6%,且地域间差异大;阿达木单抗初治队列 528 例中 67.8% 起始使用生物类似药。

要点

  • 英夫利西单抗、依那西普和阿达木单抗 3 年累积转换率分别为 14.8%、23.6% 和 66.6%
  • 阿达木单抗初治队列 528 例中 67.8% 起始使用生物类似药
  • 转换和起始生物类似药在男性和入组时 PASI 较低的患者中更常见

核心结论

  • 生物类似药的使用随时间增加,在英国和爱尔兰各地差异很大;与其他 TNFi 药物相比,阿达木单抗的生物类似药使用率最高。

研究设计与样本

  • 观察性队列研究,利用 BADBIR 注册登记数据,纳入原研药使用者队列 4202 例(英夫利西单抗 209 例、依那西普 742 例、阿达木单抗 3251 例)和阿达木单抗初治队列 528 例。
  • 原研药使用者队列分别在英夫利西单抗、依那西普和阿达木单抗专利到期时进入队列,进入日期分别为 2015 年 2 月 1 日、2015 年 8 月和 2018 年 10 月,随访至 2021 年 10 月 31 日。
  • 阿达木单抗初治队列为 2018 年 10 月 1 日至 2019 年 7 月 31 日期间开始阿达木单抗的患者。
  • 采用多变量 Cox 回归模型评估患者因素与原研药向生物类似药转换的关联,采用多变量 logistic 回归模型评估患者因素与生物类似药起始的关联。

主要发现

  • 原研药使用者队列共 4202 例,其中英夫利西单抗 209 例、依那西普 742 例、阿达木单抗 3251 例。
  • 英夫利西单抗、依那西普和阿达木单抗的原研药向生物类似药转换 3 年累积发生率分别为 14.8%、23.6% 和 66.6%。
  • 不同地理区域间 3 年转换率:英夫利西单抗从 0% 到 43.7%,依那西普从 0% 到 40.4%,阿达木单抗从 12.5% 到 84.3%。
  • 阿达木单抗初治队列 528 例中,67.8% 起始使用生物类似药。
  • 原研药向生物类似药转换和生物类似药起始在男性和入组时 PASI 较低的患者中更常见。

关键数值与推荐

  • 英夫利西单抗 3 年累积转换率为 14.8%,依那西普为 23.6%,阿达木单抗为 66.6%。
  • 英夫利西单抗 3 年转换率地域范围 0% 至 43.7%,依那西普 0% 至 40.4%,阿达木单抗 12.5% 至 84.3%。
  • 阿达木单抗初治队列中 67.8% 起始使用生物类似药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumour necrosis factor-alpha inhibitors (TNFi) have revolutionized the treatment of moderate-to-severe psoriasis. Following patent expiry of the originator biologics, TNFi biosimilars became available, presenting the opportunity for significant reductions in drug costs. OBJECTIVES: To describe the uptake of TNFi biosimilars for psoriasis treatment in the UK and Ireland. METHODS: This observational cohort study utilizes data from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR), a national pharmacovigilance study register for patients with psoriasis on systemic treatments. We analysed biosimilar uptake trends over time in nine geographical regions of England along with Wales, Scotland, Northern Ireland and the Republic of Ireland. We assessed the incidence of switching to biosimilars in an originator-user cohort (switchers). Patients on originators infliximab, etanercept and adalimumab at the time originator patents expired, entered the cohort on 1 February 2015, August 2015 and October 2018, respectively, and were followed up until 31 October 2021. Trends in biosimilar initiations were assessed in an adalimumab-naïve cohort who started adalimumab between 1 October 2018 and 31 July 2019 (starters). We assessed the associations between patient factors and originator-to-biosimilar switching and biosimilar initiation using a multivariable Cox regression model and a multivariable logistic regression model, respectively. RESULTS: Included in the originator-user cohort were 4202 patients (209 on infliximab, 742 on etanercept and 3251 on adalimumab). For infliximab, etanercept and adalimumab, respectively, the cumulative incidence of originator-to-biosimilar switching increased with time to 14.8%, 23.6% and 66.6% after 3 years. Across geographical regions, 3-year switching rates varied from 0% to 43.7% for infliximab; from 0% to 40.4% for etanercept; and from 12.5% to 84.3% for adalimumab. Out of the 528 patients included in the adalimumab-naïve cohort, 67.8% started on biosimilars. Originator-to-biosimilar switching and biosimilar initiation were more common in men and in patients who had lower Psoriasis Area and Severity Index at cohort entry. CONCLUSIONS: The uptake of biosimilars increased over time and varied considerably across the UK and Ireland; adalimumab had the highest biosimilar uptake rate compared with that of other TNFi drugs.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Phan DB, Bewley AP, Smith CH, et al. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Br J Dermatol. 2023. PMID: 37016153. doi:10.1093/bjd/ljad107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。